First‑line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature

• Maria Masvidal Hernandez ^[4] ; Sara Cros Costa ^[1] ; Carmen Salvador Coloma ^[2] ; Alicia Quilez Cutillas ^[5] ; Maria Pilar Barretina Ginesta ^[3] ; Almudena Cotes Sanchís ^[6]
  1. [1] Hospital General de Granollers

     Hospital General de Granollers

     Barcelona, España

     
  2. [2] Hospital Xàtiva Lluis Alcanyis

     Hospital Xàtiva Lluis Alcanyis

     Játiva, España

     
  3. [3] Universitat de Girona

     Universitat de Girona

     Gerona, España

     
  4. [4] Medical Oncology, Institut d’Oncologia de La Catalunya Sud, Hospital Universitari Sant Joan de Reus, Institut d’Investigació Sanitària Pere Virgili (IIPV), Universitat Rovira I Virgili, 46204 Reus, Tarragona, Spain
  5. [5] Medical Oncology. Service de Oncologie Médicale, Centre Hospitalier Universitaire de Saint Étienne, Saint‑Priest‑en‑Jarez, France
  6. [6] Medical Oncology, Hospital Virgen de La Salud-Elda, Alicante, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 2, 2025, págs. 417-424
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Ovarian cancer (OC) is the leading cause of death in women with gynecological cancers. Its diagnosis is more likely in advanced ages, with the older population being the most seen in consultations. Poly(ADP-ribose) inhibitors (PARPi) have changed OC clinical practice and evolution, showing great benefit. However, there is a lack of evidence of PARPi in elderly population that can impact the therapeutic decision and the safety/efficacy. It is necessary to avoid age as limiting factor in PARPis prescription. We conducted a review of the most relevant randomized phase III trials of maintenance PARPi after first-line treatment of advanced OC. We observed the lack of a single criterion for considering older patients, varying among trials. There is a benefit of PARPis in different populations. However, PARPi effect on quality of life is not reported, something of great relevance considering their vulnerability. Measures are needed to benefit older patients to better adapt PARPi treatment.